Frontiers in Neuroscience (Apr 2018)

Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease

  • Isabelle L. Sumner,
  • Ross A. Edwards,
  • Ayodeji A. Asuni,
  • Jessica L. Teeling

DOI
https://doi.org/10.3389/fnins.2018.00254
Journal volume & issue
Vol. 12

Abstract

Read online

There are nearly 50 million people with Alzheimer's disease (AD) worldwide and currently no disease modifying treatment is available. AD is characterized by deposits of Amyloid-β (Aβ), neurofibrillary tangles, and neuroinflammation, and several drug discovery programmes studies have focussed on Aβ as therapeutic target. Active immunization and passive immunization against Aβ leads to the clearance of deposits in humans and transgenic mice expressing human Aβ but have failed to improve memory loss. This review will discuss the possible explanations for the lack of efficacy of Aβ immunotherapy, including the role of a pro-inflammatory response and subsequent vascular side effects, the binding site of therapeutic antibodies and the timing of the treatment. We further discuss how antibodies can be engineered for improved efficacy.

Keywords